48
Participants
Start Date
March 31, 2003
Primary Completion Date
July 31, 2005
Study Completion Date
June 30, 2011
Premarin
Group A: 1.25mg once a day Group B: 1.25mg three time a day Group A has been closed and participants have been given the option of enrolling in Group B. Treamtment can continue until disease progression or serious side effects.
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Insitute, Boston
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center
OTHER
Massachusetts General Hospital
OTHER
Brigham and Women's Hospital
OTHER
Lowell General Hospital
OTHER
South Shore Hospital
OTHER
Emerson Hospital, Concord, MA
OTHER
Saint Anne's Hospital
OTHER
Dana-Farber Cancer Institute
OTHER